Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 24, 2026
TickeronGET DAILY SIGNALS
IBB vs XBI: Weighing Two Leading Biotech ETFs for Your Portfolio

IBB vs XBI: Weighing Two Leading Biotech ETFs for Your Portfolio

Key Takeaways

  • IBB is market-capitalization-weighted and dominated by large-cap biotech leaders, while XBI is modified equal-weighted, spreading exposure across small- and mid-cap names.
  • Cost differs modestly: XBI carries a 0.35% expense ratio versus IBB's 0.44%, giving XBI a slight structural cost advantage.
  • Concentration vs. breadth: IBB's top 10 holdings represent roughly half of assets, whereas XBI's top 10 make up only about 15%, reducing single-stock risk in XBI.
  • Volatility profiles diverge: XBI's small/mid-cap tilt has historically produced higher standard deviation, while IBB's large-cap anchors deliver a steadier ride.
  • Performance drivers differ: IBB is more sensitive to large-cap earnings and pipeline news, while XBI is more responsive to M&A (mergers and acquisitions), interest-rate expectations, and clinical-stage momentum.

Why These Two Biotech ETFs Stand Out

Investors looking for biotechnology exposure often compare the iShares Biotechnology ETF (IBB) and the SPDR S&P Biotech ETF (XBI). Both are passive ETFs focused on U.S. biotech, yet their weighting methods produce distinct risk and return characteristics. This distinction becomes especially relevant given shifting interest-rate expectations, ongoing M&A activity, and a busy FDA approval schedule. From what I see, recognizing these structural differences helps match the right exposure to an investor’s risk tolerance and time horizon.

Understanding IBB's Large-Cap Focus

Launched in 2001 by BlackRock, IBB tracks a modified market-capitalization-weighted index of U.S.-listed biotechnology and life sciences companies, historically the Nasdaq Biotechnology Index. It holds roughly 250 names and manages well over $10 billion in assets, with an expense ratio of 0.44%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Because of its market-cap weighting, IBB leans toward established large-cap holdings such as GILD, AMGN, VRTX, REGN, MRNA, and NTRA. The fund allocates about 82% to biotechnology and 15% to life sciences tools and services. This large-cap emphasis has typically resulted in lower volatility compared with more equal-weighted peers.

XBI's Equal-Weight Strategy

Launched in 2006 by State Street Global Advisors, XBI follows the S&P Biotechnology Select Industry Index with a modified equal-weight approach. It rebalances regularly to limit any single stock’s influence and currently holds between 130 and 170 names with multi-billion-dollar assets under management. Its expense ratio of 0.35% is lower than IBB’s. This methodology shifts emphasis toward small- and mid-cap, often clinical-stage companies. Top holdings such as MRNA, NTRA, TWST, HALO, ABBV, and IOVA each typically represent less than 3% of assets. With the top 10 holdings accounting for only about 15% of the fund, XBI offers broader single-stock diversification alongside greater exposure to higher-beta names and correspondingly higher volatility.

The Biotech Sector Environment

Both ETFs operate in a sub-sector marked by binary clinical results, substantial R&D spending, and regulatory oversight. Current themes include capital inflows supported by lower interest-rate expectations, which favor long-duration innovators, continued M&A as large pharma replenishes pipelines, and ongoing innovation in gene editing, antibody-drug conjugates, and obesity and oncology therapies. FDA cycles and drug-pricing debates add periodic risk. These dynamics tend to affect XBI’s small- and mid-cap, deal-sensitive composition more directly than IBB’s large-cap base.

Performance Differences and Positioning

Over recent cycles, XBI’s equal-weight, small/mid-cap tilt has captured stronger upside during periods of improved risk appetite, capital flows into clinical-stage names, and heightened M&A. IBB has provided more measured returns, supported by steadier earnings from large-cap holdings such as AMGN and GILD. In my view, this highlights a clear trade-off: XBI delivers higher beta and greater sensitivity to sector rotations and rate expectations, while IBB offers a more defensive, quality-oriented exposure. In risk-off periods, XBI’s higher volatility has historically led to deeper drawdowns, whereas IBB’s concentration in established names has helped limit downside.

Overall Assessment

Based on observable structural factors, Tickeron’s AI would likely favor XBI in the current environment. Its equal-weight design, broader diversification, lower 0.35% expense ratio, and greater sensitivity to sector momentum and M&A activity position it to capture upside when risk appetite for small- and mid-cap biotech remains firm. That said, this preference is probabilistic rather than absolute. IBB remains the stronger choice for investors who prioritize stability, large-cap quality, and lower volatility. The optimal selection ultimately depends on an investor’s risk tolerance, time horizon, and outlook on whether the biotech upcycle continues to favor earlier-stage, deal-sensitive names.

Enhancing My ETF Research with AI Tools

I often turn to Tickeron’s AI-powered tools when comparing ETFs like these. The platform’s ability to apply technical patterns, fundamentals, and trend strength across thousands of holdings helps me quickly identify relative positioning and potential opportunities that might otherwise require hours of manual work. It supports more systematic decisions without replacing my own judgment on risk and market context.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: IBB, XBI

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


IBB in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 16, 2026

IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 42 cases where IBB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for IBB crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Following a +4.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in 276 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

The Aroon Indicator entered an Uptrend today. In 220 of 244 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In 74 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.

The Moving Average Convergence Divergence Histogram (MACD) for IBB turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 40 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.

IBB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF (IBB) ETF is 7.93B. The market cap for tickers in the group ranges from 25.61M to 248.92B. AMGN holds the highest valuation in this group at 248.92B. The lowest valued company is AARD at 25.61M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was -6%. For the same ETF, the average monthly price growth was -6%, and the average quarterly price growth was 18%. INSM experienced the highest price growth at 17%, while UPB experienced the biggest fall at -43%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF (IBB) ETF was 29%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 47
Price Growth Rating: 61
SMR Rating: 87
Profit Risk Rating: 87
Seasonality Score: 11 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.